Micafungin Pharmazac 50 Mg

Micafungin, the active ingredient in Micafungin Pharmazac 50 Mg, is an echinocandin presented as a 50 mg injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, Candida peritonitis and is used for prophylaxis of Candida infections in hematopoietic stem cell transplant recipients. It is indicated for adult and pediatric patients with confirmed infections.

GNH USA supplies Micafungin Pharmazac 50 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation.

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

Invasive candidiasis: eradicates bloodstream Candida species in immunocompromised patients. Esophageal candidiasis: clears fungal infection of the esophageal mucosa. Candida peritonitis and intra‑abdominal infections: resolves deep-seated intra‑abdominal Candida disease. Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients: prevents invasive candidiasis in high‑risk transplant patients.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate pain. - Elevated liver enzymes: mild increase in transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury. - Severe hypersensitivity reactions: anaphylaxis, rash. - Infusion‑related reactions: hypotension, bronchospasm.

Use of Micafungin requires careful clinical assessment and monitoring. - Renal impairment: adjust monitoring as micafungin is primarily hepatic cleared. - Hepatic dysfunction: use with caution; monitor liver function tests. - Concomitant strong CYP3A4 inducers: may reduce exposure. - Pregnancy: safety not established; weigh benefits vs risks. - Pediatric use: safety and efficacy established for certain age groups; follow prescribing info. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce micafungin plasma levels. - Co‑administration with other echinocandins: increased risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin exposure. - Immunosuppressants (e.g., cyclosporine, tacrolimus): monitor levels for potential increase. - Warfarin: may enhance anticoagulant effect; monitor INR.